Methyl Donor Nutrients in Chronic Kidney Disease: Impact on the Epigenetic Landscape.
Mafra D, Esgalhado M, Borges NA, Cardozo LFMF, Stockler-Pinto MB, Craven H, Buchanan SJ, Lindholm B, Stenvinkel P, Shiels PG.
J Nutr. 2019 Feb 23.

Differences in association of lower bone mineral density with higher coronary calcification in female and male end-stage renal disease patients.
Chen Z, Qureshi AR, Brismar TB, Ripsweden J, Haarhaus M, Barany P, Heimburger O, Lindholm B, Stenvinkel P.
BMC Nephrol. 2019 18;20(1):59

Senescent cells in early vascuylar ageing and bone disease of chronic kidney disease – a novel target for treatment.
Hobson S, Arefin A, Kublickiene K, Shiels PG, Stenvinkel P.
Toxins (Basel). 2019 Feb 1;11(2).

A distinct bone phenotype in ADPKD patients with end-stage renal disease.
Evenepoel P, Claes K, Cavalier E, Meijers B, Stenvinkel P, Behets G, Jankowska M, D’Haese P, Bammens B.
Kidney Int. 2019 Feb;95(2):412-419.

The G-protein coupled receptor ChemR23 determines smooth muscle cell phenotypic switching to enhance high phosphate-induced vascular calcification.
Carracedo M, Artiach G, Witasp A, Clària J, Carlström M, Laguna-Fernandez A, Stenvinkel P, Bäck M.
Cardiovasc Res. 2018 Dec 28. doi: 10.1093/cvr/cvy316.

MicroRNAs in Acute Kidney Injury and Kidney Transplantation.
Ledeganck KJ, Gielis EM, Abramowicz A, Stenvinkel P, Shiels PG, Van Craenenbroeck AH.
Clin J Am Soc Nephrol. 2019 Jan 2. pii: CJN.08020718. doi: 10.2215/CJN.08020718.


Inverse J-shaped relation between coronary arterial calcium density and mortality in advanced chronic kidney disease.
Mukai H, Dai L, Chen Z, Lindholm B, Ripsweden J, Brismar T, Heimbürger O, Barany P, Qureshi AR, Söderberg M, Bäck M, Stenvinkel P.
Nephrol Dial Transplant. 2018 Dec 7. doi: 10.1093/ndt/gfy352.

Association of serum sclerostin with bone sclerostin in chronic kidney disease is lost in glucocorticoid treated patients.
Boltenstål H, Qureshi AR, Behets GJ, Lindholm B, Stenvinkel P, D’Haese PC, Haarhaus M. Calcif Tissue Int. 2018 Nov 7. doi: 10.1007/s00223-018-0491-4.

Mitochondrial dysfunction and gut microbiota imbalance: An intriguing relationship in chronic kidney disease.
Mafra D, Borges NA, Lindholm B, Stenvinkel P.
Mitochondrion. 2018 Nov 5. pii: S1567-7249(18)30028-X.

Fibroblast growth factor 23 is associated with fractional excretion of sodium in patients with chronic kidney disease.
Xu H, Hashem A, Witasp A, Mencke R, Goldsmith D, Barany P, Bruchfeld A, Wernerson A, Carrero JJ, Olauson H.
Nephrol Dial Transplant. 2018 Oct 11. doi: 10.1093/ndt/gfy315

Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients.
Molanaei H, Qureshi AR, Heimbürger O, Lindholm L, Diczfalusy U, Björn Anderstam B, Bertilsson L, Stenvinkel P.
BMC Pharmacol Toxicol. 2018 Jun 25;19(1):33. doi: 10.1186/s40360-018-0221-6.

The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease.
Alves FC, Sun J, Qureshi AR, Dai L, Snaedal S, Bárány P, Heimbürger O, Lindholm B, Stenvinkel P.
PLoS One. 2018 Jan 3;13(1):e0190410.

Novel treatment strategies for chronic kidney disease: insights from the animal kingdom.
Stenvinkel P, Painer J, Kuro-O M, Lanaspa M, Arnold W, Ruf T, Shiels PG, Johnson RJ.
Nat Rev Nephrol. 2018 Jan 15.

Skin autofluorescence, arterial stiffness and Framingham´s risk score for cardiovascular disease as predictors of clinical outcome in chronic kidney disease patients: A comparative analysis.
Mukai H, Svedberg O, Lindholm B, Dai L, Heimburger O, Barany P, Anderstam B, Stenvinkel P, Qureshi AR.
Nephrol Dial Transpl. In Press 2018

The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease.
Alves FC, Sun J, Qureshi AR, Dai L, Snaedal S, Bárány P, Heimbürger O, Lindholm B, Stenvinkel P.
PLoS One. 2018;13(1):e0190410.


CDKN2A/p16INK4a expression is associated with vascular progeria in chronic kidney disease.
Stenvinkel P, Luttropp L, McGuinness D, Witasp A, Qureshi AR, Wernerson A, Schalling S, Ripsweden J, Wennberg L, Söderberg S, Bárány P, Olauson O, Shiels PG.
Aging (Albany NY). 2017 9:494-507.

Rare progerin-expressing preadipocytes and adipocytes contribute to tissue depletion over time.
Revêchon G, Viceconte N, McKenna T, Sola Carvajal A, Vrtacnik P, Stenvinkel P, Lundgren L, Hultenby K, Franco I, Eriksson M.
Sci Rep. 2017 Jun 30;7(1):4405. doi: 10.1038/s41598-017-04492-0.

Pregnancy-associated plasma protein A predicts survival in end-stage renal disease – Confounding and modifying effects of cardiovascular disease, body composition and inflammation.
Nilsson E, Cao Y, Lindholm B, Ohyama A, Carrero JJ, Qureshi AR, Stenvinkel P.
Nephrol Dial Transplant. 2017 Oct 1;32(10):1776. doi: 10.1093/ndt/gfx266.

Renal volumetry with magnetic resonance imaging.
Christensen RH, Lundgren T, Stenvinkel P, Brismar TB.
Acta Radiol Open. 2017 Sep 14;6(9):2058460117731120.

Sclerostin─A Debutant on the Autosomal Dominant Polycystic Kidney Disease Scene?
Jankowska M, Haarhaus M, Qureshi AR, Lindholm B, Evenepoel P, Stenvinkel P.
Kidney Int Rep. 2017 Jan 10;2(3):481-485.

HDL from end-stage renal disease patients exhibits superior cardioprotection and increase in S1P.
Brinck J, Thomas A, Lauer E, Frej C, Dahlbäck B, Stenvinkel P, James RW, Frias M.
In Press Eur, J Clin Invest 2018

Plasma Beta-Trace Protein as a Marker of Residual Renal Function: The Effect of Different Hemodialysis Modalities and Intra-Individual Variability over Time.
Van Craenenbroeck AH, Bragfors-Helin A-C, Qureshi AR, Lindholm L, Sjöberg B, Anderstam B, Olof Heimburger O, Stenvinkel P, Bárány P.
Kidney Blood Press Res 2017;42:877-885

Clinical global assessment of nutritional status as predictor of mortality in chronic kidney disease patients.
Dai L, Mukai H, Lindholm B, Heimbürger O, Barany P, Stenvinkel P, Qureshi AR.
PLoS One. 2017 Dec 6;12(12):e0186659.


Does statins promote vascular calcification in chronic kidney disease?
Chen Z, Qureshi AR, Parini P, Hurt-Camejo E, Ripsweden J, Brismar TB, Barany P, Jaminon A, Schurgers LJ, Heimburger O, Lindholm B, Stenvinkel P.
Eur J Clin Invest. 2016 Dec 30. doi: 10.1111/eci.12718. PMID: 28036114

Increased Telomere Attrition After Renal Transplantation-Impact of Antimetabolite Therapy.
Luttropp K, Nordfors L, McGuinness D, Wennberg L, Curley H, Quasim T, Genberg H, Sandberg J, Sönnerborg I, Schalling M, Qureshi AR, Bárány P, Shiels PG, Stenvinkel P.
Transplant Direct. 2016 Nov 16;2(12):e116. eCollection 2016. PMID: 27990481

Bone mineral density of extremities associates with coronary calcification and biopsy verified vascular calcification in living donor renal transplant recipients.
Chen Z, Haarhaus M, Barany P, Wennberg L, Ripsweden J, Brismar TB, Lindholm L, Wernerson A, Stenvinkel P, Qureshi AR .
Journal of Bone and Mineral Metabolism, In Press 2016

Increased Telomere Attrition Following Renal Transplantation – Impact of Anti-Metabolite Therapy
Luttropp L Nordfors, L McGuinness D, Wennberg L, Genberg H, Sandberg J, Sönnerborg I, Schalling M, Qureshi AR, Bárány P, Paul G Shiels PG, Stenvinkel P.
Transpl Direct In Press 2016

Vertebral bone density associates with coronary artery calcification and is an independent predictor of poor outcome in end-stage renal disease patients
Chen Z, Qureshi AR, Wennberg L, Lindholm B, Barany P, Haarhaus M, Brismar TB, Stenvinkel P.
Bone. 2016;92:50-57.
PMID: 27519971

Distinct subpopulations of FOXD1 stroma-derived cells regulate renal erythropoietin.
Kobayashi H, Liu Q, Binns TC, Urrutia AA, Davidoff O, Kapitsinou PP, Pfaff AS, Olauson H, Wernerson A, Fogo AB, Fong GH, Gross KW, Haase VH.
J Clin Invest. 2016 May 2;126(5):1926-38. doi: 10.1172/JCI83551. Epub 2016 Apr 18.
PMID: 27088801



Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification.
Qureshi AR, Olauson H, Witasp A, Haarhaus M, Brandenburg V, Wernerson A, Lindholm B, Söderberg M, Wennberg L, Nordfors L, Ripsweden J, Barany P, Stenvinkel P.
Kidney Int. 2015 Dec;88(6):1356-1364. doi: 10.1038/ki.2015.194. Epub 2015 Sep 2.
PMID: 26331407